Pharma Journalist -

Degenerative disc disease has long been considered an inseparable part of aging but new breakthrough research from SpinalCyte suggests a new cell-based therapy could provide a cure for…
Read More...

Biopharmaceutical company MOLOGEN AG declared having signed a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its…
Read More...

In a bid to treat metastatic radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC), Exelixis declared results from a Phase 2 Investigator-sponsored trial of cabozantinib.…
Read More...

Merck declared that it will rescind protocol 019 also termed as the APECS study assessing verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid…
Read More...

European Commission extends approval to Celltrion's Herzuma for treatment of patients with early breast Cancer, metastatic breast cancer or metastatic gastric cancer whose tumors have…
Read More...

Strong biologics, biosimilars and injectable drug-delivery device pipelines for pharma companies coupled with the increased workload in producing these and increasing trends in…
Read More...

Horizon Discovery Group plc announces that it has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer for Horizon's proprietary…
Read More...

DNAnexus announced the availability of its Clinical Trial Solution (CTS) which streamlines the use of next-generation sequencing (NGS) data in regulated clinical trials. The company…
Read More...

Applied Therapeutics announced initiation of a Phase 1 clinical trial for AT-001, an oral small molecule in development for diabetic complications. The Phase 1 clinical trial is a…
Read More...

Teva Pharmaceutical announced the launch of generic version of Syprine (trientine hydrochloride) capsules, 250 mg, in the U.S. Trientine hydrochloride is used in the treatment of…
Read More...